Advertisement

Management of Complications of CRS and HIPEC

  • Aditi Bhatt
  • Akash M. Mehta
Chapter

Abstract

The potential clinical benefits of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have for long been overshadowed by its relatively high morbidity and mortality compared to other surgical procedures. It takes 3–12 months on an average for the quality of life to return to normal. With standardization of indications, better patient selection, development and implementation of perioperative care pathways and institution of formal teaching programs, there has been a reduction in the overall morbidity and mortality from the procedure, and it is now similar to that of other major gastrointestinal surgeries when performed in specialized centres. Morbidity has a negative impact on the overall survival in certain cancers (including colorectal cancer) and can delay the administration of systemic therapy which is equally important in other cancers like ovarian cancer which further emphasizes the importance of patient selection. It may result in a significant additional financial burden where such procedures are not under ‘insurance cover’ and are ‘out-of-pocket’ spending for patients. The 90-day morbidity and mortality capture the overall complication rate more accurately and should be recorded and reported instead of the 30-day morbidity and mortality. Early recognition and management of complications by multidisciplinary teams are needed to ‘rescue’ patients who develop complications.

Keywords

Complications CRS HIPEC 30-day morbidity 90-day morbidity Mortality 

References

  1. 1.
    Seretis C, Youssef H. Quality of life after cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: a systematic review. Eur J Surg Oncol. 2014;40:1605–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Jacquet P, Stephens AD, Averbach AM, Chang D, Ettinghausen SE, Dalton RR, Steves MA, Sugarbaker PH. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer. 1996;77:2622–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Stephens AD, Alderman R, Chang D, Edwards GD, Esquivel J, Sebbag G, Steves MA, Sugarbaker PH. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6:790–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Glehen O, Osinsky D, Cotte E, Kwiatkowski F, Freyer G, Isaac S, Trillet-Lenoir V, Sayag-Beaujard AC, François Y, Vignal J, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol. 2003;10:863–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM, Steinberg SM, Liewehr DJ, Kleiner DE, Alexander HR. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21:4560–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kusamura S, Younan R, Baratti D, Costanzo P, Favaro M, Gavazzi C, Deraco M. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion: analysis of morbidity and mortality in 209 peritoneal surface malignancies treated with closed abdomen technique. Cancer. 2006;106:1144–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei--a report of 103 procedures. Eur J Surg Oncol. 2006;32:186–90.PubMedCrossRefGoogle Scholar
  9. 9.
    Stewart JH, Shen P, Russell GB, Bradley RF, Hundley JC, Loggie BL, Geisinger KR, Levine EA. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol. 2006;13:624–34.PubMedCrossRefGoogle Scholar
  10. 10.
    Sugarbaker PH, Alderman R, Edwards G, Marquardt CE, Gushchin V, Esquivel J, Chang D. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol. 2006;13:635–44.PubMedCrossRefGoogle Scholar
  11. 11.
    Unalp HR, Kamer E, Kar H, Bal A, Peskersoy M, Ali Onal M. Urgent abdominal re-explorations. World J Emerg Surg. 2006;1:10.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Elias D, Goere D, Blot F, Billard V, Pocard M, Kohneh-Shahri N, Raynard B. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol. 2007;14:1818–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Yan TD, Zappa L, Edwards G, Alderman R, Marquardt CE, Sugarbaker PH. Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database. J Surg Oncol. 2007;96(2):102–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Dowdy SC, Loewen RT, Aletti G, Feitoza SS, Cliby W. Assessment of outcomes and morbidity following diaphragmatic peritonectomy for women with ovarian carcinoma. Gynecol Oncol. 2008;109(2):303–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15:754–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.  https://doi.org/10.1200/JCO.2009.23.9285.PubMedCrossRefGoogle Scholar
  17. 17.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer. 2010;116:5608–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Mizumoto A, Canbay E, Hirano M, et al. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single institution in Japan. Gastroenterol Res Pract. 2012;2012., Article ID 836425:5.  https://doi.org/10.1155/2012/836425.CrossRefGoogle Scholar
  20. 20.
    Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39:1435–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Kuijpers AM, Mirck B, Aalbers AG, et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol. 2013;20:4224–30.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Levine EA, Stewart JH, Shen P, et al. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014;218:573–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Baumgartner JM, Kwong TG, Ma GL, Messer K, Kelly KJ, Lowy AM. A novel tool for predicting major complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(5):1609–17.  https://doi.org/10.1245/s10434-015-5012-3. Epub 2015 Dec 17PubMedCrossRefGoogle Scholar
  25. 25.
    Moran B, Cecil T, Chandrakumaran K, et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Color Dis. 2015;17:772–8.CrossRefGoogle Scholar
  26. 26.
    Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796–803.  https://doi.org/10.1002/jso.24248. Epub 2016 Apr 25PubMedCrossRefGoogle Scholar
  27. 27.
    Loungnarath R, Causeret S, Bossard N, Faheez M, Sayag-Beaujard AC, Brigand C, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum. 2005;48(7):1372–9.  https://doi.org/10.1007/s10350-005-0045-5.PubMedCrossRefGoogle Scholar
  28. 28.
    Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy–a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol. 2007;14(8):2270–80.  https://doi.org/10.1245/s10434-007-9406-8.PubMedCrossRefGoogle Scholar
  29. 29.
    Simkens GA, van Oudheusden TR, Luyer MD, et al. Predictors of severe morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2016;23:833–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Bartlett EK, Meise C, Roses RE, et al. Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database. Ann Surg Oncol. 2014;21:1494–500.PubMedCrossRefGoogle Scholar
  31. 31.
    Pinar U, Tremblay JF, Passot G, et al. Reconstruction after ureteral resection during HIPEC surgery: re-implantation with uretero-neocystostomy seems safer than end-to-end anastomosis. J Visc Surg. 2017;154(4):227–30.  https://doi.org/10.1016/j.jviscsurg.2017.01.002.PubMedCrossRefGoogle Scholar
  32. 32.
    Baratti D, Kusamura S, Mingrone E, et al. Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg. 2012;256:334–41.PubMedCrossRefGoogle Scholar
  33. 33.
    Votanopoulos KI, Swords DS, Swett KR, et al. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol. 2013;20:3899–904.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    McPartland SJ, Goodman MD. The effect of elevated body mass index on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014;21:1463–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Franko J, Gusani NJ, Holtzman MP, Ahrendt SA, Jones HL, Zeh HJ, Bartlett DL. Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol. 2008;15(11):3065–72.PubMedCrossRefGoogle Scholar
  36. 36.
    Ahmed S, Levine EA, Randle RW, et al. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21:4226–31.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Franssen B, Tabrizian P, Weinberg A, et al. Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement. Ann Surg Oncol. 2015;22:1639–44.PubMedCrossRefGoogle Scholar
  38. 38.
    Schwarz L, Votanopoulos K, Morris D, et al. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable? Results of an international multicenter study. Ann Surg. 2015;263(2):369–75. [Epub ahead of print]CrossRefGoogle Scholar
  39. 39.
    Glockzin G, Renner P, Popp FC, et al. Hepatobiliary procedures in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2011;18:1052–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Randle RW, Doud AN, Levine EA, et al. Peritoneal surface disease with synchronous hepatic involvement treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015;22:1634–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Turner KM, Hanna NN, Zhu Y, et al. Assessment of neoadjuvant chemotherapy on operative parameters and outcome in patients with peritoneal dissemination from high-grade appendiceal cancer. Ann Surg Oncol. 2013;20:1068–73.PubMedCrossRefGoogle Scholar
  42. 42.
    Deraco M, Baratti D, Hutanu I, et al. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1093–100.PubMedCrossRefGoogle Scholar
  43. 43.
    Ceelen W, Van Nieuwenhove Y, Putte DV, et al. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ann Surg Oncol. 2014;21:3023–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Eveno C, Passot G, Goéré D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21:1792–800.PubMedCrossRefGoogle Scholar
  45. 45.
    Voron T, Eveno C, Jouvin I, et al. Cytoreductive surgery with a hyperthermic intraperitoneal chemotherapy program: safe after 40 cases, but only controlled after 140 cases. Eur J Surg Oncol. 2015;41:1671–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Mohamed F, Moran BJ. Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer J. 2009;15(3):196–9.  https://doi.org/10.1097/PPO.0b013e3181a58d56.PubMedCrossRefGoogle Scholar
  47. 47.
    Malfroy S, Wallet F, Maucort-Boulch D, Chardonnal L, Sens N, Friggeri A, Passot G, Glehen O, Piriou V. Complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis: risk factors for ICU admission and morbidity prognostic score. Surg Oncol. 2016;25(1):6–15.  https://doi.org/10.1016/j.suronc.2015.11.003. Epub 2015 Nov 6PubMedCrossRefGoogle Scholar
  48. 48.
    Mise Y, Vauthey JN, Zimmitti G, et al. Ninety-day postoperative mortality is a legitimate measure of hepatopancreatobiliary surgical quality. Ann Surg. 2015;262:1071–8.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Schwarz L, Bruno M, Parker NH, et al. Active surveillance for adverse events within 90 days: the standard for reporting surgical outcomes after pancreatectomy. Ann Surg Oncol. 2015;22:3522–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ. Is the combination of distal pancreatectomy and cytoreductive surgery with HIPEC reasonable?: results of an International Multicenter Study. Ann Surg. 2016;263(2):369–75.  https://doi.org/10.1097/SLA.0000000000001225.PubMedCrossRefGoogle Scholar
  51. 51.
    Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Pelz JO, Germer CT. Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion. Der Chir Z fur alle Geb der Oper Med. 2013;84:957–61.Google Scholar
  53. 53.
    Younan R, Kusamura S, Baratti D, et al. Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol. 2008;98:253–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Khuri SF, Daley J, Henderson W, et al. The Department of Veterans Affairs’ NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg. 1998;228:491–507.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9–13.PubMedCrossRefGoogle Scholar
  56. 56.
    Clavien P, Sanabria J, Strasberg S. Proposed classification of complication of surgery with examples of utility in cholecystectomy. Surgery. 1992;111:518–26.PubMedGoogle Scholar
  57. 57.
    Pomposelli JJ, Gupta SK, Zacharoulis DC, et al. Surgical complication outcome (SCOUT) score: a new method to evaluate quality of care in vascular surgery. J Vasc Surg. 1997;25:1007–14. discussion 1014–1015PubMedCrossRefGoogle Scholar
  58. 58.
    Gawande AA, Thomas EJ, Zinner MJ, et al. The incidence and nature of surgical adverse events in Colorado and Utah in 1992. Surgery. 1999;126:66–75.PubMedCrossRefGoogle Scholar
  59. 59.
    Veen MR, Lardenoye JW, Kastelein GW, et al. Recording and classification of complications in a surgical practice. Eur J Surg. 1999;165:421–4. discussion 425.PubMedCrossRefGoogle Scholar
  60. 60.
    Pillai SB, van Rij AM, Williams S, et al. Complexity-and risk-adjusted model for measuring surgical outcome. Br J Surg. 1999;86:1567–72.PubMedCrossRefGoogle Scholar
  61. 61.
    Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.  https://doi.org/10.1097/01.sla.0000133083.54934.ae.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Clavien PA, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187–96.PubMedCrossRefGoogle Scholar
  63. 63.
    Slankamenac K, Graf R, Puhan MA, et al. Perception of surgical complications among patients, nurses and physicians: a prospective cross-sectional survey. Patient Saf Surg. 2011;5:30.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Vonlanthen R, Slankamenac K, Breitenstein S, et al. The impact of complications on costs of major surgical procedures: a cost analysis of 1200 patients. Ann Surg. 2011;254:907–13.PubMedCrossRefGoogle Scholar
  65. 65.
    Chouliaras K, Levine EA, Fino N, Shen P, Votanopoulos KI. Prognostic factors and significance of gastrointestinal leak after Cytoreductive Surgery (CRS) with Heated Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2017;24:890–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Slankamenac K, et al. The comprehensive complication index: a novel and more sensitive endpoint for assessing outcome and reducing sample size in randomized controlled trials. Ann Surg. 2014;260(5):757–62.PubMedCrossRefGoogle Scholar
  67. 67.
    Lehmann K, Eshmuminov D, Slankamenac K, Kranzbühler B, Clavien PA, Vonlanthen R, Gertsch P. Where oncologic and surgical complication scoring systems collide: time for a new consensus for CRS/HIPEC. World J Surg. 2016 May;40(5):1075–81.  https://doi.org/10.1007/s00268-015-3366-0.PubMedCrossRefGoogle Scholar
  68. 68.
    Katayama H, Kurokawa Y, Nakamura K, et al. Extended Clavien-Dindo classification of surgical complications: Japan clinical oncology group postoperative complications criteria. Surg Today. 2016;46:668–85.  https://doi.org/10.1007/s00595-015-1236-x.PubMedCrossRefGoogle Scholar
  69. 69.
    Sugarbaker PH, Van der Speeten K, Stuart OA, Chang D, Mahteme H. Patient- and treatment-related variables, adverse events and their statistical relationship for treatment of peritoneal metastases. In: Sugarbaker PH, editor. Cytoreductive surgery & perioperative chemotherapy for peritoneal surface malignancy: textbook and video atlas. Woodbury: Ciné-Med; 2012. p. 183–206.Google Scholar
  70. 70.
    Silber JH, Williams SV, Krakauer H, Schwartz JS. Hospital and patient characteristics associated with death after surgery: a study of adverse occurrence and failure to rescue. Med Care. 1992;30:615–29.PubMedCrossRefGoogle Scholar
  71. 71.
    Ghaferi AA, Birkmeyer JD, Dimick JB. Complications, failure-to-rescue and mortality with major inpatient surgery in medicare patients. Ann Surg. 2009;250:1029–34.PubMedCrossRefGoogle Scholar
  72. 72.
    Mercier F, Cotte E, Glehen O, Passot G. Why morbidity is not an adequate metric for evaluation of surgical quality. Ann Surg. 2017.  https://doi.org/10.1097/SLA.0000000000002256.
  73. 73.
    Passot G, Vaudoyer D, Villeneuve L, Wallet F, Beaujard AC, Boschetti G, Rousset P, Bakrin N, Cotte E, Glehen O. A perioperative clinical pathway can dramatically reduce failure-to-rescue rates after cytoreductive surgery for peritoneal carcinomatosis: a retrospective study of 666 consecutive cytoreductions. Ann Surg. 2017;265(4):806–13.  https://doi.org/10.1097/SLA.0000000000001723.PubMedCrossRefGoogle Scholar
  74. 74.
    Aloia TA, Zimmitti G, Conrad C, et al. Return to intended oncologic treatment: a novel metric for evaluating the quality of oncosurgical therapy for malignancy. J Surg Oncol. 2014;110:107–14.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Elias D, Di Pietrantonio D, Boulet T, Honore C, Bonnet S, Goere D, Kohneh-Shahri N, Raynard B. “Natural history” of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35:434–8.PubMedCrossRefGoogle Scholar
  76. 76.
    Baratti D, Kusamura S, Laterza B, Balestra MR, Deraco M. Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastrointest Oncol. 2010;2(1):36–43.  https://doi.org/10.4251/wjgo.v2.i1.36.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Hansson J, Graf W, Påhlman L, Nygren P, Mahteme H. Postoperative adverse events and long-term survival after cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2009;35(2):202–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Youssef H, Newman C, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ. Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin. Dis Colon Rectum. 2011;54(3):293–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Casado-Adam A, Alderman R, Anthony Stuart O, Chang D, Sugarbaker PH. Gastrointestinal complications in 147 consecutive patients with peritoneal surface malignancy treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Int J Surg Oncol. 2011;2011., Article ID 468698:10.  https://doi.org/10.1155/2011/468698.Google Scholar
  80. 80.
    Fujita F, Torashima Y, Kuroki T, Eguchi S. Risk factors and predictive factors for anastomotic leakage after resection for colorectal cancer: reappraisal of the literature. Surg Today. 2014;44:1595–602.PubMedCrossRefGoogle Scholar
  81. 81.
    Valle SJ, Alzahrani N, Alzahrani S, Traiki TB, Liauw W, Morris DL. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: incidence, management and outcomes. Surg Oncol. 2016;25(3):315–20.  https://doi.org/10.1016/j.suronc.2016.05.025. PubMedCrossRefGoogle Scholar
  82. 82.
    Younan R, Kusamura S, Baratti D, Oliva GD, Costanzo P, Favaro M, Gavazzi C, Deraco M. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2005;12(11):910–8.PubMedCrossRefGoogle Scholar
  83. 83.
    Fumagalli U, Trabucchi E, Soligo M, et al. Effects of intraperitoneal chemotherapy on anastomotic healing in the rat. J Surg Res. 1991;50:82–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Makrin V, Lev-Chelouche D, Even Sapir E, et al. Intraperitoneal heated chemotherapy affects healing of experimental colonic anastomosis: an animal study. J Surg Oncol. 2005;89:18–22.PubMedCrossRefGoogle Scholar
  85. 85.
    Kuzu MA, Köksoy C, Kale T, Demirpençe E, Renda N. Experimental study of the effect of preoperative 5-fluorouracil on the integrity of colonic anastomoses. Br J Surg. 1998;85:236–9.PubMedCrossRefGoogle Scholar
  86. 86.
    Arikan AY, Günal O, Pehlivan M, Alper M. The effect of intraperitoneal paclitaxel administration on colonic anastomosis. Hepato-Gastroenterology. 2000;47:1273–6.PubMedGoogle Scholar
  87. 87.
    Shimizu T, Maeta M, Koga S. Influence of local hyperthermia on the healing of small intestinal anastomoses in the rat. Br J Surg. 1991;78:57–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Elias D, Antoun S, Goharin A, Otmany AE, Puizilout JM, Lasser P. Research on the best chemohyperthermia technique of treatment of peritoneal carcinomatosis after complete resection. Int J Surg Investig. 2000;1:431–9.PubMedGoogle Scholar
  89. 89.
    Sarnaik AA, Sussman JJ, Ahmad SA, Lowy AM. Technology of intraperitoneal chemotherapy administration: a survey of techniques with a review of morbidity and mortality. Surg Oncol Clin North Am. 2003;12:849–63.CrossRefGoogle Scholar
  90. 90.
    Deraco M, Rossi CR, Pennacchioli E, et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori. 2001;87:120–6.PubMedGoogle Scholar
  91. 91.
    Zanon C, Clara R, Bortolini M, et al. Chemohyperthermia for advanced abdominal malignancies: a new procedure with closed abdomen and previously performed anastomosis. Int J Hyperth. 2001;17:456–64.CrossRefGoogle Scholar
  92. 92.
    European Society of Coloproctology Collaborating Group. The relationship between method of anastomosis and anastomotic failure after right hemicolectomy and ileo-caecal resection: an international snapshot audit. Color Dis. 2017.  https://doi.org/10.1111/codi.13646.
  93. 93.
    de Cuba EM, Verwaal VJ, de Hingh IH, et al. Morbidity associated with colostomy reversal after cytoreductive surgery and HIPEC. Ann Surg Oncol. 2014;21:883–90.PubMedCrossRefGoogle Scholar
  94. 94.
    Whealon MD, Gahagan JV, Sujatha-Bhaskar S, et al. Is Fecal diversion needed in pelvic anastomoses during Hyperthermic Intraperitoneal Chemotherapy (HIPEC)? Ann Surg Oncol. 2017;24:2122–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Sugarbaker PH. Avoiding diverting ileostomy in patients requiring complete pelvic peritonectomy. Ann Surg Oncol. 2016;23:1481–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Evers DJ, Smeenk RM, Bottenberg PD, et al. Effect of preservation of the right gastro-epiploic artery on delayed gastric emptying after cytoreductive surgery and HIPEC: a randomized clinical trial. Eur J Surg Oncol. 2011;37:162–7.PubMedCrossRefGoogle Scholar
  97. 97.
    Di Fabio F, Mehta A, Chandrakumaran K, et al. Advanced Pseudomyxoma peritonei requiring gastrectomy to achieve complete cytoreduction results in good long-term oncologic outcomes. Ann Surg Oncol. 2016;23:4316–21.PubMedCrossRefGoogle Scholar
  98. 98.
    Burke S, Abu-Wasel B, Eid A, Nissan A, Hanani M. Differential effect of hyperthermia on nerves and smooth muscle of the mouse ileum. J Surg Oncol. 2011;103:92–100.PubMedCrossRefGoogle Scholar
  99. 99.
    Vather R, Trivedi S, Bissett I. Defining postoperative ileus: results of a systematic review and global survey. J Gastrointest Surg. 2013;17:962–72.PubMedCrossRefGoogle Scholar
  100. 100.
    Milligan DW, Raftery AT. Observations on the pathogenesis of peritoneal adhesions: a light and electron microscopical study. Br J Surg. 1974;61:2.CrossRefGoogle Scholar
  101. 101.
    Jackson BB. Observations of intraperitoneal adhesions; an experimental study. Surgery. 1958;44:507–14.PubMedGoogle Scholar
  102. 102.
    Honoré C, Sourrouille I, Suria S, et al. Postoperative peritonitis without an underlying digestive fistula after complete cytoreductive surgery plus HIPEC. Saudi J Gastroenterol. 2013;19(6):271–7.  https://doi.org/10.4103/1319-3767.121033.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis. 1996;23:486–94.PubMedCrossRefGoogle Scholar
  104. 104.
    Bosscha K, van Vroonhoven TJ, van der Werken C. Surgical management of severe secondary peritonitis. Br J Surg. 1999;86:1371–7.PubMedCrossRefGoogle Scholar
  105. 105.
    MacFie J. Current status of bacterial translocation as a cause of surgical sepsis. Br Med Bull. 2004;71:1–11.PubMedCrossRefGoogle Scholar
  106. 106.
    Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol. 2003;10:972–92.PubMedCrossRefGoogle Scholar
  107. 107.
    Angele MK, Chaudry IH. Surgical trauma and immunosuppression: pathophysiology and potential immunomodulatory approaches. Langenbeck’s Arch Surg. 2005;390:333–41.CrossRefGoogle Scholar
  108. 108.
    Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793–808.PubMedCrossRefGoogle Scholar
  109. 109.
    Milligan DW, Raferty AT. Observations on the pathogen is of peritoneal adhesions: a light and electron microscopical study. Br J Surg. 1974;61:274.PubMedCrossRefGoogle Scholar
  110. 110.
    Jacquet P, Sugarbaker PH. Abdominal adhesions causing intestinal obstruction following cytoreductive surgery and early postoperative intraperitoneal chemotherapy. Acta Chir Austriaca. 1995;27:92.  https://doi.org/10.1007/BF02602252.CrossRefGoogle Scholar
  111. 111.
    Ferguson MK. The effect of antineoplastic agents on wound healing. Surg Gynecol Obstet. 1982;154:421–8.PubMedGoogle Scholar
  112. 112.
    Wimizer T, Orda R, Bawnik JB, et al. Mitomycin and the healing of intestinal anastomosis. Arch Surg. 1973;106:314.CrossRefGoogle Scholar
  113. 113.
    Hopkins MP, Shellhaas C, Clark T, et al. The effect of immediate carboplatinum on wound healing. Gynecol Oncol. 1993;51:210–3.PubMedCrossRefGoogle Scholar
  114. 114.
    di Zerega GS, Rodgers KE. Prevention of postoperative adhesion. In: di Zerega GS, Rodgers KE, editors. The peritoneum. New York: Springer; 1992. p. 307.Google Scholar
  115. 115.
    Yaacobi Y, Goldberg EP. Effect of ringer’s lactate irrigation on the formation of postoperative abdominal adhesions. J Invest Surg. 1991;4:31–6.PubMedCrossRefGoogle Scholar
  116. 116.
    Kehoe SM, Williams NL, Yakubu R, Levine DA, Chi DS, Sabbatini PJ, Aghajanian CA, Barakat RR, Abu-Rustum NR. Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies. Gynecol Oncol. 2009;113(2):228–32.  https://doi.org/10.1016/j.ygyno.2009.01.016. PubMedCrossRefGoogle Scholar
  117. 117.
    Dagbert F, Thievenaz R, Decullier E, Bakrin N, Cotte E, Rousset P, Vaudoyer D, Passot G, Glehen O. Splenectomy increases postoperative complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23(6):1980–5.  https://doi.org/10.1245/s10434-016-5147-x. PubMedCrossRefGoogle Scholar
  118. 118.
    Becher RD, Shen P, Stewart JH, Russell G, Bradley JF, Levine EA. Splenectomy ameliorates hematologic toxicity of hyperthermic intraperitoneal chemotherapy. J Gastrointest Oncol. 2011;2(2):70–6.  https://doi.org/10.3978/j.issn.2078-6891.2011.011. PubMedPubMedCentralGoogle Scholar
  119. 119.
    Delaitre B, Champault G, Barrat C, Gossot D, Bresler L, Meyer C, Collet D, Samama G. Laparoscopic splenectomy for hematologic diseases. Study of 275 cases. French Society of Laparoscopic Surgery. Ann Chir. 2000;125(6):522–9.PubMedCrossRefGoogle Scholar
  120. 120.
    Hendricks T, Martens MF, Huyben CM, Wobbes T. Inhibition of basal and TGF beta-induced fibroblast collagen synthesis by antineoplastic agents. Implications for wound healing. Br J Cancer. 1993;67(3):545–50.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Kusamura S, Baratti D, Antonucci A, Younan R, Laterza B, Oliva GD, Gavazzi C, Deraco M. Incidence of postoperative pancreatic fistula and hyperamylasemia after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2007;14(12):3443–52.PubMedCrossRefGoogle Scholar
  122. 122.
    Downs-Canner S, Ding Y, Magge DR, et al. A comparative analysis of postoperative pancreatic fistulas after surgery with and without Hyperthermic Intraperitoneal Chemoperfusion. Ann Surg Oncol. 2015;22(5):1651–7.  https://doi.org/10.1245/s10434-014-4186-4.PubMedCrossRefGoogle Scholar
  123. 123.
    Swaroop VS, Chari ST, Clain JE. Severe acute pancreatitis. JAMA. 2004;291(23):2865–8.PubMedCrossRefGoogle Scholar
  124. 124.
    Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M. International study group on pancreatic fistula definition. Postoperative pancreatic fistula: an International Study Group (ISGPF) definition. Surgery. 2005;138(1):8–13.PubMedCrossRefGoogle Scholar
  125. 125.
    Tansung T, Sugarbaker PH. Management of pancreatitis due to pancreatic injury in cytoreductive surgery. Reg Cancer Treat. 1995;8:180–4.Google Scholar
  126. 126.
    Kehoe SM, Eisenhauer EL, Abu-Rustum NR, et al. Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer. Gynecol Oncol. 2009;112:496–500.PubMedCrossRefGoogle Scholar
  127. 127.
    Saxena A, Chua TC, Yan TD, et al. Postoperative pancreatic fistula after cytoreductive surgery and perioperative intraperitoneal chemotherapy: incidence, risk factors, management, and clinical sequelae. Ann Surg Oncol. 2010;17:1302–10.PubMedCrossRefGoogle Scholar
  128. 128.
    Makino I, Kitagawa H, Nakagawara H, et al. The management of a remnant pancreatic stump for preventing the development of postoperative pancreatic fistulas after distal pancreatectomy: current evidence and our strategy. Surg Today. 2013;43:595–602.PubMedCrossRefGoogle Scholar
  129. 129.
    Votanopoulos KI, Randle RW, Craven B, et al. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014;21:868–74.PubMedCrossRefGoogle Scholar
  130. 130.
    Braam HJ, van Oudheusden TR, de Hingh IH, et al. Urological procedures in patients with peritoneal carcinomatosis of colorectal cancer treated with HIPEC: morbidity and survival analysis. Anticancer Res. 2015;35:295–300.PubMedGoogle Scholar
  131. 131.
    Lyon TD, Turner Ii RM, Nikonow TN, et al. Effect of a concomitant urologic procedure on outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2016;113:218–22.PubMedCrossRefGoogle Scholar
  132. 132.
    Canet J, Gallart L, Gomar C, et al. Prediction of postoperative pulmonary complications in a population-based surgical cohort. Anesthesiology. 2010;113:1338–50.PubMedCrossRefGoogle Scholar
  133. 133.
    Chiumello D, Chevallard G, Gregoretti C. Non-invasive ventilation in postoperative patients: a systematic review. Intensive Care Med. 2011;37:918–29.PubMedCrossRefGoogle Scholar
  134. 134.
    Futier E, Paugam-Burtz C, Godet T, et al. Effect of early postextubation high-flow nasal cannula vs conventional oxygen therapy on hypoxaemia in patients after major abdominal surgery: a French multicentre randomised controlled trial (OPERA). Intensive Care Med. 2016;42:1888–98.PubMedCrossRefGoogle Scholar
  135. 135.
    Osseis M, Weyrech J, Gayat E, et al. Epidural analgesia combined with a comprehensive physiotherapy program after cytoreductive surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: a retrospective study of 124 patients. Eur J Surg Oncol. 2016;42:1938–43.PubMedCrossRefGoogle Scholar
  136. 136.
    Boden I, Browning L, Skinner EH, et al. The LIPPSMAck POP (lung infection prevention post surgery – major abdominal – with pre-operative physiotherapy) trial: study protocol for a multi-centre randomised controlled trial. Trials. 2015;16:573.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Duggan M, Kavanagh BR. Atelectasis in the perioperative patient. Curr Opin Anaesthesiol. 2007;20:37–42.  https://doi.org/10.1097/ACO.0b013e328011d7e5.PubMedCrossRefGoogle Scholar
  138. 138.
    Reinius H, Jonsson L, Gustafsson S, Sundbom M, Duvernoy O, Pelosi P, Hedenstierna G, Fredén F. Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis. Anesthesiology. 2009;111:979–87.  https://doi.org/10.1097/ALN.0b013e3181b87edb.PubMedCrossRefGoogle Scholar
  139. 139.
    Casado D, López F, Marti R. Perioperative fluid management and major respiratory complications in patients undergoing esophagectomy. Dis Esophagus. 2010;23:523–8.  https://doi.org/10.1111/j.1442-2050.2010.01057.x.PubMedCrossRefGoogle Scholar
  140. 140.
    Kita T, Mammoto T, Kishi Y. Fluid management and postoperative respiratory disturbances in patients with transthoracic esophagectomy for carcinoma. J Clin Anesth. 2002;14:252–6.  https://doi.org/10.1016/S0952-8180(02)00352-5.PubMedCrossRefGoogle Scholar
  141. 141.
    Chéreau E, Ballester M, Selle F, et al. Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG. 2009;116(8):1062–8.PubMedCrossRefGoogle Scholar
  142. 142.
    Preti V, Chang D, Sugarbaker PH. Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients. Gastroenterol Res Pract. 2012;2012:8.  https://doi.org/10.1155/2012/635314. CrossRefGoogle Scholar
  143. 143.
    Chen MY, Chiles C, Loggie BW, Choplin RH, Perini MA, Fleming RA. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol. 1997;66:19–23.PubMedCrossRefGoogle Scholar
  144. 144.
    Orwoll ES, Kiessling PJ, Patterson JR. Interstitial pneumonia from mitomycin. Ann Intern Med. 1978;89:352–5.PubMedCrossRefGoogle Scholar
  145. 145.
    Batist G, Andrews JL Jr. Pulmonary toxicity of antineoplastic drugs. JAMA. 1981;246:1449–53.PubMedCrossRefGoogle Scholar
  146. 146.
    Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol. 1982;9:34–51.PubMedGoogle Scholar
  147. 147.
    Raue W, Tsilimparis N, Bloch A, Menenakos C, Hartmann J. Volume therapy and cardio circular function during hyperthermic intraperitoneal chemotherapy. Eur Surg Res. 2009;43:365–72.  https://doi.org/10.1159/000248164.PubMedCrossRefGoogle Scholar
  148. 148.
    Schmidt C, Creutzenberg M, Piso P, Hobbhahn J, Bucher M. Peri-operative anaesthetic management of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Anaesthesia. 2008;63:389–95.  https://doi.org/10.1111/j.1365-2044.2007.05380.x.PubMedCrossRefGoogle Scholar
  149. 149.
    Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(1):53–8.PubMedCrossRefGoogle Scholar
  150. 150.
    ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, et al. Acute respiratory distress syndrome: the berlin definition. JAMA. 2012;307:2526–33.Google Scholar
  151. 151.
    National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006;354:2213–24.CrossRefGoogle Scholar
  152. 152.
    Alonso O, Sugarbaker PH. Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy: case reports and a review of the literature. Am Surg. 2000;66(11):1032–6.PubMedGoogle Scholar
  153. 153.
    Eltabbakh GH, Awtrey CS, Walker P. Adult respiratory distress syndrome after extensive cytoreductive surgery. A case report. J Reprod Med. 2000;45:51–4.PubMedGoogle Scholar
  154. 154.
    Abel ML, Kokosis G, Blazer DG. Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC. World J Surg Oncol. 2017;15:49.PubMedPubMedCentralCrossRefGoogle Scholar
  155. 155.
    Thompson CC, Bailey MK, Conroy JM, Bromley HR. Postoperative pulmonary toxicity associated with mitomycin-C therapy. South Med J. 1992;85:1257–9.PubMedCrossRefGoogle Scholar
  156. 156.
    Gonzalez-Moreno S, Lambert LA, Mansfield PF. Interstitial pneumonitis: an exceptional toxicity of hyperthermic intraperitoneal mitomycin C. Eur J Surg Oncol. 2008;34:482–4.PubMedCrossRefGoogle Scholar
  157. 157.
    Verweij J, van Zanten T, Souren T, Golding R, Pinedo HM. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer. 1987;60:756–61.PubMedCrossRefGoogle Scholar
  158. 158.
    van Ruth S, Verwaal VJ, Zoetmulder FA. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12:771–80.PubMedCrossRefGoogle Scholar
  159. 159.
    Rottenstreich A, Kalish Y, Kleinstern G, et al. Factors associated with thromboembolic events following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017.  https://doi.org/10.1002/jso.24746.
  160. 160.
    Vukadinovic V, Chiou JD, Morris DL. Clinical features of pulmonary emboli in patients following cytoreductive surgery (peritonectomy) and hyperthermic intraperitoneal chemotherapy (hipec), a single centre experience. Eur J Surg Oncol. 2015;41:702–6.PubMedCrossRefGoogle Scholar
  161. 161.
    Giglio MT, Marucci M, Testini M, Brienza N. Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials. Br J Anaesth. 2009;103:637–46.PubMedCrossRefGoogle Scholar
  162. 162.
    Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270–382.PubMedCrossRefGoogle Scholar
  163. 163.
    Thanigaimani K, Mohamed F, Cecil T, Moran BJ, Bell J. The use of cardiac output monitoring to guide the administration of intravenous fluid during hyperthermic intraperitoneal chemotherapy. Color Dis. 2013;15:1537–42.CrossRefGoogle Scholar
  164. 164.
    Colantonio L, Claroni C, Fabrizi L, et al. A randomized trial of goal directed vs. standard fluid therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Gastrointest Surg. 2015;19:722–9.PubMedCrossRefGoogle Scholar
  165. 165.
    Schmidt C, Moritz S, Rath S, et al. Perioperative management of patients with cytoreductive surgery for peritoneal carcinomatosis. J Surg Oncol. 2009;100:297–301.PubMedCrossRefGoogle Scholar
  166. 166.
    Vorgias G, Iavazzo C, Mavromatis J, et al. Determination of the necessary total protein substitution requirements in patients with advanced stage ovarian cancer and ascites, undergoing debulking surgery. Correlation with plasma proteins. Ann Surg Oncol. 2007;14:1919–23.PubMedCrossRefGoogle Scholar
  167. 167.
    Schnake KJ, Sugarbaker PH, Yoo D. Neutropenia following perioperative intraperitoneal chemotherapy. Tumori. 1999;85:41–6.PubMedGoogle Scholar
  168. 168.
    Lambert LA, Armstrong TS, Lee JJ, et al. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16:2181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251:896–901.PubMedCrossRefGoogle Scholar
  170. 170.
    Sargant N, Roy A, Simpson S, et al. A protocol for management of blood loss in surgical treatment of peritoneal malignancy by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Transfus Med. 2016;26:118–22.PubMedCrossRefGoogle Scholar
  171. 171.
    Delhorme JB, Sattler L, Severac F, et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor? Eur J Surg Oncol. 2017;43(6):1095–101.  https://doi.org/10.1016/j.ejso.2017.01.015.PubMedCrossRefGoogle Scholar
  172. 172.
    Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315–22.PubMedCrossRefGoogle Scholar
  173. 173.
    Mehta AM, Huitema AD, Burger JW, et al. Standard clinical protocol for bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): systemic leucovorin, 5-fluorouracil, and heated intraperitoneal oxaliplatin in a chloride-containing carrier solution. Ann Surg Oncol. 2017;24:990–7.PubMedCrossRefGoogle Scholar
  174. 174.
    Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–42.  https://doi.org/10.1016/j.ygyno.2016.05.032. Epub 2016 Jun 2.
  175. 175.
    Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC. HIPEC ROC I: a phase 1 study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136:699–708.  https://doi.org/10.1002/ijc.29011.PubMedGoogle Scholar
  176. 176.
    Tsukamoto JS, Belotto de Oliveira M, Peixoto RD. Tonic-clonic seizure following cytoreductive surgery with intraperitoneal oxaliplatin: a case report and review of the literature. Case Rep Oncol. 2016;9(1):89–94.  https://doi.org/10.1159/000443827.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Macri A, Fleres F, Ieni A, et al. Wernicke encephalopathy as rare complication of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Surg Case Rep. 2015;16:29–32.PubMedPubMedCentralCrossRefGoogle Scholar
  178. 178.
    Lampl B, Leebmann H, Mayr M, Piso P. Rare diaphragmatic complications following cytoreductive surgery and HIPEC: report of two cases. Surg Today. 2014;44(2):383–6.PubMedCrossRefGoogle Scholar
  179. 179.
    Laterza B, Baratti D, Cozzi G, et al. Colobronchial fistula: an unusual complication after peritonectomy and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC). In Vivo. 2009;23(1):151–3.PubMedGoogle Scholar
  180. 180.
    Ihemelandu C, Mavros MN, Sugarbaker P. Adverse events postoperatively had no impact on long-term survival of patients treated with cytoreductive surgery with heated intraperitoneal chemotherapy for appendiceal cancer with peritoneal metastases. Ann Surg Oncol. 2016;23:4231–7.PubMedCrossRefGoogle Scholar
  181. 181.
    Simkens GA, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2014;22(8):2656–62.PubMedCrossRefGoogle Scholar
  182. 182.
    Passot G, Vaudoyer D, Villeneuve L, Wallet F, Beaujard AC, Boschetti G, Rousset P, Bakrin N, Cotte E, Glehen O. A perioperative clinical pathway can dramatically reduce failure-to-rescue rates after cytoreductive surgery for peritoneal carcinomatosis: a retrospective study of 666 consecutive cytoreductions. Ann Surg. 2017;265(4):806–13.  https://doi.org/10.1097/SLA.0000000000001723.

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyFortis HospitalBangaloreIndia
  2. 2.Division of Peritoneal Malignancy & Colorectal SurgeryPeritoneal Malignancy InstituteBasingstokeUK
  3. 3.North Hampshire Hospital, Hampshire Hospitals NHS Foundation TrustBasingstokeUK

Personalised recommendations